Literature DB >> 33500170

Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation.

Harini Narayanan1, Fabian Dingfelder2, Alessandro Butté3, Nikolai Lorenzen4, Michael Sokolov3, Paolo Arosio5.   

Abstract

Successful biologics must satisfy multiple properties including activity and particular physicochemical features that are globally defined as developability. These multiple properties must be simultaneously optimized in a very broad design space of protein sequences and buffer compositions. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of protein properties, increasing their activity and safety as well as decreasing their development time and manufacturing costs. We highlight the emerging applications of ML in biologics discovery and development, focusing on protein engineering, early biophysical screening, and formulation. We discuss the power of ML in extracting information from complex datasets and in reducing the necessary experimental effort to simultaneously achieve multiple quality targets. We finally anticipate possible future interventions of AI in several steps of the biological landscape.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords:  antibodies; biologics development; developability; formulation; machine learning; protein engineering

Year:  2021        PMID: 33500170     DOI: 10.1016/j.tips.2020.12.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  7 in total

Review 1.  Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies.

Authors:  Rahmad Akbar; Habib Bashour; Puneet Rawat; Philippe A Robert; Eva Smorodina; Tudor-Stefan Cotet; Karine Flem-Karlsen; Robert Frank; Brij Bhushan Mehta; Mai Ha Vu; Talip Zengin; Jose Gutierrez-Marcos; Fridtjof Lund-Johansen; Jan Terje Andersen; Victor Greiff
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

2.  Cluster learning-assisted directed evolution.

Authors:  Yuchi Qiu; Jian Hu; Guo-Wei Wei
Journal:  Nat Comput Sci       Date:  2021-12-09

3.  Conformational Entropy as a Potential Liability of Computationally Designed Antibodies.

Authors:  Thomas Löhr; Pietro Sormanni; Michele Vendruscolo
Journal:  Biomolecules       Date:  2022-05-18

Review 4.  Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.

Authors:  Rahul Khetan; Robin Curtis; Charlotte M Deane; Johannes Thorling Hadsund; Uddipan Kar; Konrad Krawczyk; Daisuke Kuroda; Sarah A Robinson; Pietro Sormanni; Kouhei Tsumoto; Jim Warwicker; Andrew C R Martin
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

5.  Modulating Glycoside Hydrolase Activity between Hydrolysis and Transfer Reactions Using an Evolutionary Approach.

Authors:  Rodrigo A Arreola-Barroso; Alexey Llopiz; Leticia Olvera; Gloria Saab-Rincón
Journal:  Molecules       Date:  2021-10-30       Impact factor: 4.411

6.  In silico proof of principle of machine learning-based antibody design at unconstrained scale.

Authors:  Rahmad Akbar; Philippe A Robert; Cédric R Weber; Michael Widrich; Robert Frank; Milena Pavlović; Lonneke Scheffer; Maria Chernigovskaya; Igor Snapkov; Andrei Slabodkin; Brij Bhushan Mehta; Enkelejda Miho; Fridtjof Lund-Johansen; Jan Terje Andersen; Sepp Hochreiter; Ingrid Hobæk Haff; Günter Klambauer; Geir Kjetil Sandve; Victor Greiff
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

7.  An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.

Authors:  Norbert Furtmann; Marion Schneider; Nadja Spindler; Bjoern Steinmann; Ziyu Li; Ingo Focken; Joachim Meyer; Dilyana Dimova; Katja Kroll; Wulf Dirk Leuschner; Audrey Debeaumont; Magali Mathieu; Christian Lange; Werner Dittrich; Jochen Kruip; Thorsten Schmidt; Joerg Birkenfeld
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.